Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Exenatide
Drug ID BADD_D00862
Description Exenatide is a glucagon-like peptide-1 (GLP-1) analog[Label]. It functions to activate the GLP-1 receptor and increases insulin secretion, decrease glucagon secretion, and slow gastric emptying to improve glycemic control[Label]. Exenatide was given FDA approval on April 28, 2005[L6106].
Indications and Usage Indicated as adjunctive therapy to improve glycemic control in patients with Type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of both, but have not achieved adequate glycemic control.
Marketing Status Prescription
ATC Code A10BJ01
DrugBank ID DB01276
KEGG ID D04121
MeSH ID D000077270
PubChem ID 45588096
TTD Drug ID D00YVF
NDC Product Code 52416-125; 69766-078; 52416-105; 0310-6512; 41524-0003; 0406-7310; 0310-6524; 0310-6530; 0310-6540; 62756-040
Synonyms Exenatide | Bydureon | ITCA 650 | AC 2993 LAR | Exendin-4 | Ex4 Peptide | Peptide, Ex4 | Exendin 4 | Byetta | AC 2993
Chemical Information
Molecular Formula C184H282N50O60S
CAS Registry Number 141758-74-9
SMILES CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN )C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC( C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC( =O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C( CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO )NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC (=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Angioedema23.04.01.001; 10.01.05.009--Not Available
Asthenia08.01.01.001--Not Available
Blood creatinine increased13.13.01.004--
Complications of transplanted kidney20.01.02.005; 12.02.09.011--Not Available
Constipation07.02.02.001--
Dehydration14.05.05.001--
Diarrhoea07.02.01.001--
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.007--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Eructation07.01.02.003--
Feeling jittery08.01.09.016--Not Available
Flatulence07.01.04.002--
Gastrooesophageal reflux disease07.02.02.003--
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypoglycaemia14.06.03.001; 05.06.03.001--
Injection site reaction12.07.03.015; 08.02.03.014--
International normalised ratio increased13.01.02.008--
Nausea07.01.07.001--
Pancreatitis acute07.18.01.002--Not Available
Pancreatitis haemorrhagic07.18.01.003--Not Available
Pancreatitis necrotising07.18.01.004--Not Available
Rash macular23.03.13.003--Not Available
Rash papular23.03.13.017--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Urticaria23.04.02.001; 10.01.06.001--
The 1th Page    1 2    Next   Last    Total 2 Pages